Economy
Astra’s Experimental Stomach Cancer Drug Doubled Survival Time
AstraZeneca Plc’s experimental stomach cancer drug doubled the time patients survived in a late-stage trial, boosting prospects for a potential new blockbuster.
Publication and source
PublicationSanalda Haber
SourceBloomberg
Published
CategoryEconomy
Summary from the source publisher’s news feed.